Skip to main content
Clinical Trials/NCT05851820
NCT05851820
Completed
Not Applicable

Prevalence and Impact of Diabetes Mellitus in Hospitalized COVID-19 Patients in a Tunisian Center: a Cross Sectional Study

Sana Rouis1 site in 1 country866 target enrollmentSeptember 25, 2020

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Prevalence
Sponsor
Sana Rouis
Enrollment
866
Locations
1
Primary Endpoint
Admission to Intensive Care Units
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

Objective: The objective of this study was to evaluate the prevalence and impact of diabetes mellitus on the severity and mortality of COVID-19.

Methods: Data of laboratory-confirmed hospitalized patients at the COVID-19 unit of Ibn El Jazzar University Hospital in Kairouan between September 2020 and August 2021 were analysed, in a cross-sectional study. The population was classified into two groups (COVID-19 patients with versus without diabetes). Primary outcomes were the overall length of hospital stay, the admission to the intensive care unit (ICU), and death.

Detailed Description

The outbreak of the coronavirus disease 2019 (Covid-19) has become an evolving worldwide health crisis. With the rising prevalence of diabetes mellitus has come an increasing awareness of their impacts on infectious diseases, and the risk for post-infection complications and mortality from critical infections. Objective: The objective of this study was to evaluate the prevalence and impact of diabetes mellitus on the severity and mortality of COVID-19. Methods: Data of laboratory-confirmed hospitalized patients at the COVID-19 unit of Ibn El Jazzar University Hospital in Kairouan between September 2020 and August 2021 were analysed, in a cross-sectional study. The population was classified into two groups (COVID-19 patients with versus without diabetes). Primary outcomes were the overall length of hospital stay, the admission to the intensive care unit (ICU), and death. Association between diabetes and death was assessed in a Cox proportional hazards model.

Registry
clinicaltrials.gov
Start Date
September 25, 2020
End Date
August 31, 2021
Last Updated
2 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Sana Rouis
Responsible Party
Sponsor Investigator
Principal Investigator

Sana Rouis

Assistant professor in Infectious Diseases

Faculty of Medicine, Sousse

Eligibility Criteria

Inclusion Criteria

  • Confirmed cases indicated the patients whose real-time reverse transcriptase-polymerase chain reaction (RT-PCR) analysis results for nasal swab specimens were positive.

Exclusion Criteria

  • the investigators didn't included patients who were suspected cases, and whose the result of PCR test was negative ; Covid-19 patients admitted in other departments (Cardiology, pediatrics, obstetrics, intensive care unit, medicine, surgery department...) ; and patients with missing medical records. -

Outcomes

Primary Outcomes

Admission to Intensive Care Units

Time Frame: 7 days

patients who were transferred to ICU

death

Time Frame: 7 days

patients who were dead

overall length of hospital stay

Time Frame: 7 days

length of hospital stay from admission to discharge (or transfer or death)

Study Sites (1)

Loading locations...

Similar Trials